HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Divests Non-Core OTCs To Focus On "Priority Brands," Emerging Markets

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline will divest non-core OTC products to accelerate consumer health care growth and help fund a share buy-back program following a financial wipeout in the firm's most recent quarter.

You may also be interested in...

Central, Eastern Europe Lead OTC Growth On Sector’s Top Continent

Central and Eastern Europe continue to drive OTC sales growth on the continent, with even low-growth countries matching the best levels in Western Europe.

Prestige CEO Mannelly Sees Change In Retail "Headwinds" Giving Brands More Shelf Space

In a year-and-a-half of heading Prestige Brands Holdings, Matthew Mannelly has been a change agent for the consumer health products firm.

GSK's Sensodyne With NovaMin Enters Oral-Care Sensitivity Competition

GlaxoSmithKline announces the U.K. launch of Sensodyne Repair & Protect toothpaste as the first consumer oral-care product containing the NovaMin technology GSK acquired in 2009.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts